Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fulgent Genetics Inc.

18.76
-0.2800-1.47%
Volume:103.97K
Turnover:1.96M
Market Cap:579.04M
PE:-13.28
High:19.12
Open:18.95
Low:18.68
Close:19.04
Loading ...

Company Profile

Company Name:
Fulgent Genetics Inc.
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
1313
Office Location:
4399 Santa Anita Avenue,El Monte,California,United States
Zip Code:
91731
Fax:
626 454 1667
Introduction:
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Directors

Name
Position
Ming Hsieh
President, Chief Executive Officer and Chairman
James J. Mulay
Director
John Bolger
Director
Yun Yen
Director

Shareholders

Name
Position
Ming Hsieh
President, Chief Executive Officer and Chairman
Paul Kim
Chief Financial Officer
Hanlin Gao
Chief Scientific Officer and Lab Director